Rising Tides and Targeted Science Funding: The Gain for Basic Research

A key point of Harvey Black's Feb. 18 article in The Scientist on targeted research initiatives and earmarking of funds1—that, by sidestepping peer review, this practice may subvert scientific inquiry and, more specifically, reduce funds for basic research—is a valid concern. However, criticism of targeted research programs on this tenet alone amounts to throwing the baby out with the bathwater. After all, these initiatives are often created to fill specific needs otherwise unmet or

Written byJeff Cheek
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Admittedly, I am a biased observer on this issue. Colorado was one of the few states with the foresight to invest some of its proceeds (from the national Master Settlement Agreement with the tobacco industry) in research focused on tobacco use and its consequences. Modeled after the highly successful research program in California, which is supported by a tax on tobacco products,2 the Colorado Tobacco Research Program (CTRP) funds a broad portfolio of projects ranging from molecular biology to policy analysis. Coordinated by the California program, CTRP applications undergo a rigorous peer review modeled after that of the National Institutes of Health. While this ensures that scientific excellence is maintained, the fact remains that our programs are mandated to support only research that is relevant to our mission—programs such as ours are indeed "targeted."

Ideally, a comprehensive funding agency should balance its support for both basic and applied sciences, since ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies